BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32942186)

  • 1. 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAF
    El-Damasy AK; Haque MM; Park JW; Shin SC; Lee JS; EunKyeong Kim E; Keum G
    Eur J Med Chem; 2020 Dec; 208():112756. PubMed ID: 32942186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
    El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
    Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
    El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
    Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
    Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
    Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
    Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.
    El-Gamal MI; Khan MA; Tarazi H; Abdel-Maksoud MS; Gamal El-Din MM; Yoo KH; Oh CH
    Eur J Med Chem; 2017 Feb; 127():413-423. PubMed ID: 28088086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
    Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
    Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.
    Li X; Shen J; Tan L; Zhang Z; Gao D; Luo J; Cheng H; Zhou X; Ma J; Ding K; Lu X
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2760-2763. PubMed ID: 27155899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
    El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
    Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers.
    El-Sharief AMS; Ammar YA; Belal A; El-Sharief MAMS; Mohamed YA; Mehany ABM; Elhag Ali GAM; Ragab A
    Bioorg Chem; 2019 Apr; 85():399-412. PubMed ID: 30665034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
    Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
    Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
    Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
    Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents.
    Zhou Y; Yan W; Cao D; Shao M; Li D; Wang F; Yang Z; Chen Y; He L; Wang T; Shen M; Chen L
    Eur J Med Chem; 2017 Sep; 138():1114-1125. PubMed ID: 28763646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.
    Abdel-Maksoud MS; Ammar UM; Oh CH
    Bioorg Med Chem; 2019 May; 27(10):2041-2051. PubMed ID: 30955995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.
    Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G
    Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.
    Abdelatef SA; El-Saadi MT; Amin NH; Abdelazeem AH; Omar HA; Abdellatif KRA
    Eur J Med Chem; 2018 Apr; 150():567-578. PubMed ID: 29549841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
    Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of potent B-Raf
    Wang ZF; Wang PF; Ma JT; Chai YZ; Hu HM; Gao WL; Wang ZC; Wang BZ; Zhu HL
    Chem Biol Drug Des; 2018 Feb; 91(2):567-574. PubMed ID: 29045039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
    Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
    Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.